How should the vaccine be distributed? Ezekiel Emanuel has a plan


When effective Covid-19 vaccines are developed, they will be scarce for a while. The World Health Organization (WHO), global leaders, and vaccine producers are already facing the question of national and international allocation. And while there is vocal commitment to "fair and equitable" distribution, what exactly does "fair and equitable" look like?

Nineteen global health experts have proposed a new, three-phase plan for distributing a vaccine for Covid-19. Published this week in Science, the paper was led by Ezekiel J. Emanuel, of the University of Pennsylvania.

Two main proposals have emerged. Some argue that health care workers and high-risk populations, such as people over 65, should be immunized first. The WHO, on the other hand, suggests that countries receive doses proportional to their populations.

From an ethical perspective, both of these strategies are "seriously flawed," according to the article in Science

"The idea of distributing vaccines by population appears to be an equitable strategy," Emanuel said. "But the fact is that normally, we distribute things based on how severe there is suffering in a given place, and, in this case, we argue that the primary measure of suffering ought to be the number of premature deaths that a vaccine would prevent."

In their proposal, the authors analyse the situation from a principalist standpoint, which they call the Fair Priority Model. Its aim is to mitigate three types of harms: death and permanent organ damage, indirect health consequences, such as health care system strain and stress, as well as economic destruction.

Of all of these dimensions, preventing death -- especially premature death -- is particularly urgent, the authors argue, which is the focus of Phase 1 of the Fair Priority Model. Premature deaths from COVID-19 are determined in each country by calculating "standard expected years of life lost," a commonly-used global health metric. In Phase 2, the authors propose two metrics that capture overall economic improvement and the extent to which people would be spared from poverty. And in Phase 3, countries with higher transmission rates are initially prioritized, but all countries should eventually receive sufficient vaccines to halt transmission -- which is projected to require that 60 to 70% of the population be immune.

The WHO plan, by contrast, begins with 3 percent of each country's population receiving vaccines, and continues with population-proportional allocation until every country has vaccinated 20% of its citizens.

Emanuel and his coauthors argue that, while that plan may be politically tenable, it "mistakenly assumes that equality requires treating differently-situated countries identically, rather than equitably responding to their different needs." In reality, equally populous countries are facing dramatically different levels of death and economic devastation from the pandemic.

The authors also object to a plan that would prioritize countries according to the number of front-line health care workers, the proportion of the population over 65, and the number of people with comorbidities within each country. They say that preferentially immunizing health care workers -- who already have access to personal protective equipment (PPE) and other advanced infectious disease prevention methods -- likely would not substantially reduce harm in higher-income countries.

Similarly, focusing on vaccinating countries with older populations would not necessarily reduce the spread of the virus or minimize death. Moreover, low- and middle-income countries have fewer older residents and health care workers per capita than higher-income countries.

"What you end up doing is giving a lot of vaccine to rich countries, which doesn't seem like the goal of fair and equitable distribution," Emanuel said.

Michael Cook is editor of BioEdge




MORE ON THESE TOPICS | coronavirus, vaccines

This article is published by Michael Cook and BioEdge under a Creative Commons licence. You may republish it or translate it free of charge with attribution for non-commercial purposes following these guidelines. If you teach at a university we ask that your department make a donation. Commercial media must contact us for permission and fees. Some articles on this site are published under different terms.

 
 Search BioEdge

 Subscribe to BioEdge newsletter
rss Subscribe to BioEdge RSS feed

 
comments powered by Disqus